Antitrust: Commission sends Statement of Objections to Teva on ‘pay for delay’ pharma agreement

The European Commission has informed pharmaceutical company Teva of its preliminary view that an agreement concluded with Cephalon was in breach of EU antitrust rules. Under the agreement, Teva committed not to market a cheaper generic version of Cephalon's drug for sleep disorders, modafinil.   Margrethe Vestager, Commissioner in charge of competition policy, said: "Market entry … Continue reading Antitrust: Commission sends Statement of Objections to Teva on ‘pay for delay’ pharma agreement